2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Jonathan Douxfils, Dorothy Adcock, Shannon M Bates, Emmanuel J Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Prof Dr Edelgard Lindhoff-Last, Steve Kitchen, Robert Charles Gosselin

Research output: Contribution to journalArticlepeer-review

47 Downloads (Pure)


In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

Original languageEnglish
Pages (from-to)1008-1020
Number of pages13
JournalThrombosis and Haemostasis
Issue number8
Early online date19 Mar 2021
Publication statusPublished - 1 Aug 2021


  • diagnosis management
  • direct oral anticoagulants
  • guidance
  • laboratory

Cite this